🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Hims & Hers Health declines as Lilly launches single-dose vials of Zepbound

Published 08/27/2024, 09:47 AM
Updated 08/27/2024, 10:14 AM
©  Reuters
LLY
-
HIMS
-

Hims & Hers Health saw its shares decline by more than 6% on Tuesday morning in response to Eli Lilly (NYSE:LLY)'s latest announcement.

Lilly said it has introduced single-dose vials of its obesity medication, Zepbound, priced at a 50% discount compared to other incretin medicines. This move comes amid growing competition in the obesity treatment market.

Lilly's new offering includes 2.5 mg and 5 mg single-dose vials priced at $399 and $549 for a four-week supply, respectively. This pricing significantly undercuts the list prices of competing medicines.

The vials will be available through Lilly's direct-to-patient service, LillyDirect, and are designed to provide a more affordable option for those paying out-of-pocket, without the need for insurance coverage.

According to Citi analysts, Lilly's initiative represents a "shot across the bow" for companies involved in the GLP-1 compounders space, including Hims & Hers Health.

The analysts noted that Lilly's move aims to address concerns about "counterfeit, fake, unsafe or untested knock-offs" and is a direct challenge to compounded alternatives in the market.

Hims & Hers currently sells compounded semaglutide, a product that might now face heightened competition from this branded option.

The single-dose vials of Zepbound are expected to drive higher consumer confidence due to their brand assurance, which could impact companies like Hims & Hers.

The implications of Lilly's new pricing strategy could intensify market pressures on similar players such as HIMS.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.